[Atezolizumab in non-small cell lung cancer]
Virgilio S, Ciapponi A, González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A.
Record ID 32018001441
Original Title: Atezolizumab en cáncer de pulmón de células no pequeñas
Authors' recomendations: CONCLUSIONS High quality evidence showed that treatment with atezolizumab compared with docetaxel as second line therapy in adult patients with advanced non-small cell lung cancer improves overall survival in approximately 4 months; however, no differences in progression free survival were determined. Moderate quality evidence from indirect comparisons showed differences in overall or progression free survival when comparing therapy with atezolizumab versus other immune therapy alternatives such as nivolumab or pembrolizumab. The clinical practice guidelines consulted consider atezolizumab as a second-line therapy alternative after having received platinum therapy in patients with non-small cell lung cancer patients. The coverage policies consulted from United States sponsors, both public and private, cover it. The European and Latin American public sponsors consulted do not include this technology in their coverage list.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.